Get Your 7-Day Free Trial! Start Now!
Get Premium to unlock powerful stock data
NAS:ASND (Denmark)  
Manual of Stocks™
Ascendis Pharma A/S logo

Ascendis Pharma A/S

$ 92.96 -1.24 (-1.32%) 04:00 PM EST
Warning! GuruFocus has detected 6 Severe warning signs with ASND. Subscribe to check it out.
P/E:
At Loss
P/B:
7.05
Market Cap:
$ 5.19B
Enterprise V:
$ 4.73B
Volume:
312.40K
Avg Vol (2M):
553.42K
Also Trade In:
Volume:
312.40K
Market Cap $:
5.19B
PE Ratio:
At Loss
Avg Vol (2-Month):
553.42K
Enterprise Value $:
4.73B
PB Ratio:
7.05
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Ascendis Pharma A/S
NAICS : 325411 SIC : 2833
http://www.ascendispharma.com
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Compare
Compare
NAS:IONS • NYSE:DNA • NAS:ALKS • NAS:MRVI • NAS:APLS • NAS:CRSP • NAS:EXEL • NAS:LEGN • NAS:CERE • NAS:SRPT • OCSE:NOVO B • ASX:CSL • NAS:REGN • NAS:VRTX • NAS:MRNA • XKRX:207940 • NAS:BNTX • HKSE:02269 • NAS:SGEN • SZSE:300122
Traded in other countries / regions
A1SN34.Brazil • A71.Germany • ASND.Mexico • ASND.USA
Description
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Financial Strength

5/10
Name Current Vs Industry Vs History
Cash-To-Debt 2.07
Equity-to-Asset 0.49
Debt-to-Equity 0.7
Debt-to-EBITDA -1.1
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.9
Distress
Grey
Safe
Beneish M-Score -1.52
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

4/10
Name Current Vs Industry Vs History
5-Day RSI 70.69
9-Day RSI 63.54
14-Day RSI 57.77
6-1 Month Momentum % -33.61
12-1 Month Momentum % -33.87

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 11.76
Quick Ratio 10.79
Cash Ratio 10.26
Days Inventory 6557.34
Days Sales Outstanding 47.07
Days Payable 5505.26

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -10.6

Financials (Next Earnings Date:2022-08-25 Est.)

ASND's 30-Y Financials

Guru Trades

See Details
To
EMBED
 SAVE

Insider Trades

See Details
To
EMBED
 SAVE

Gurus Latest Trades with NAS:ASND

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
 SAVE
Dividend
To
EMBED
 SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

GF Value: $306.87
ASND
EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 15.595
EPS (TTM) ($) -9.287
Beta 0.92
Volatility % 45.52
14-Day RSI 57.77
14-Day ATR ($) 5.301165
20-Day SMA ($) 86.6265
12-1 Month Momentum % -33.87
52-Week Range ($) 61.5791 - 178.71
Shares Outstanding (Mil) 55.8

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Ascendis Pharma A/S Filings

Document Form Filing Date
No Filing Data

Headlines

See More
Get Premium to unlock powerful stock data
Product
Home
Site Map
Mobile App
Email Alerts
中文
Business
Advertise
Referral Program
Affiliate Program
Information
Career
RSS
FAQ
Contact Us
About
About Us
ADV Part 2A
ADV Part 2B
ADV Part 3
Term of Use
Privacy Policy
Affiliate Program
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. Detailed
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.
© 2004-2022 GuruFocus.com, LLC. All Rights Reserved.